National incidence of autoimmune liver diseases and its relationship with the human development index

Pan, Hongying; Dai, Yining; Zheng, Ji-Na; Shi, Ke‐Qing; Poucke, Sven Van; Zou, Hai; Zheng, Ming‐Hua

doi:10.18632/oncotarget.10090

Cited by 10 publications

(14 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past two decades, there have been a chain of epidemiological retrospective investigations concerning patients with PBC[15-22]. The epidemiology of PBC has not only changed significantly over the past twenty years, with a trend towards increasing prevalence in many places around the world[15-22], but is also positively correlated with the national HDI[13]. There is a positive, but not significant, correlation between PBC incidence and HDI on a global level ( r = 0.348, P = 0.082)[13].…”

Section: Altered Terminology For Pbc: From “Primary Biliary Cirrhosismentioning

confidence: 99%

“…The epidemiology of PBC has not only changed significantly over the past twenty years, with a trend towards increasing prevalence in many places around the world[15-22], but is also positively correlated with the national HDI[13]. There is a positive, but not significant, correlation between PBC incidence and HDI on a global level ( r = 0.348, P = 0.082)[13]. However, in Europe, a significantly positive correlation exists between PBC incidence and HDI ( r = 0.455, P = 0.044)[13].…”

Section: Altered Terminology For Pbc: From “Primary Biliary Cirrhosismentioning

confidence: 99%

“…There is a positive, but not significant, correlation between PBC incidence and HDI on a global level ( r = 0.348, P = 0.082)[13]. However, in Europe, a significantly positive correlation exists between PBC incidence and HDI ( r = 0.455, P = 0.044)[13]. Moreover, the PBC incidence is positively related to the health index ( r = 0.422, P = 0.036), but negatively related to the education index ( r = -0.650, P < 0.01)[13].…”

Section: Altered Terminology For Pbc: From “Primary Biliary Cirrhosismentioning

confidence: 99%

“…PBC predominantly affects women, at a ratio of approximately 12:1 of women to men, who are normally diagnosed at middle-age, primarily in an initial symptomless early stage[9-12]. There is positive association between the national incidence of PBC and socioeconomic status, as estimated by the Human Development Index (HDI)[13]. Moreover, in less-developed countries, the incidence of PBC might be less common[13].…”

Section: Introductionmentioning

confidence: 99%

“…There is positive association between the national incidence of PBC and socioeconomic status, as estimated by the Human Development Index (HDI)[13]. Moreover, in less-developed countries, the incidence of PBC might be less common[13]. Fatigue and pruritus are incipient clinical manifestations that appear in approximately 20% of PBC patients[14].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Huang¹

2016

WJH

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC), formerly referred to as primary biliary cirrhosis, is an infrequent progressive intrahepatic cholestatic autoimmune illness that can evolve into hepatic fibrosis, hepatic cirrhosis, hepatic failure, and, in some cases, hepatocellular carcinoma. The disease itself is characterized by T-lymphocyte-mediated chronic non-suppurative destructive cholangitis and elevated serum levels of extremely specific anti-mitochondrial autoantibodies (AMAs). In this article, we will not only review epidemiology, risk factors, natural history, predictive scores, radiologic approaches (e.g., acoustic radiation force impulse imaging, vibration controlled transient elastography, and magnetic resonance elastography), clinical features, serological characteristics covering biochemical markers, immunoglobulins, infections markers, biomarkers, predictive fibrosis marker, specific antibodies (including AMAs such as AMA-M2), anti-nuclear autoantibodies [such as anti-multiple nuclear dot autoantibodies (anti-sp100, PML, NDP52, anti-sp140), anti-rim-like/membranous anti-nuclear autoantibodies (anti-gp210, anti-p62), anti-centromere autoantibodies, and some of the novel autoantibodies], histopathological characteristics of PBC, diagnostic advances, and anti-diastole of PBC. Furthermore, this review emphasizes the recent advances in research of PBC in terms of therapies, including ursodeoxycholic acid, budesonide, methotrexate, obeticholic acid, cyclosporine A, fibrates such as bezafibrate and fenofibrate, rituximab, mesenchymal stem cells transplant, and hepatic transplant. Currently, hepatic transplant remains the only optimal choice with acknowledged treatment efficiency for end-stage PBC patients.

show abstract

Section: Altered Terminology For Pbc: From “Primary Biliary Cirrhosismentioning

confidence: 99%

Section: Altered Terminology For Pbc: From “Primary Biliary Cirrhosismentioning

confidence: 99%

Section: Altered Terminology For Pbc: From “Primary Biliary Cirrhosismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Huang¹

2016

WJH

View full text Add to dashboard Cite

show abstract

Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts

Trivedi,

Hirschfield,

Adams

et al. 2024

Gastroenterology

View full text Add to dashboard Cite

Role of microbiome in autoimmune liver diseases

et al. 2023

View full text Add to dashboard Cite

The microbiome plays a crucial role in integrating environmental influences into host physiology, potentially linking it to autoimmune liver diseases, such as autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. All autoimmune liver diseases are associated with reduced diversity of the gut microbiome and altered abundance of certain bacteria. However, the relationship between the microbiome and liver diseases is bidirectional and varies over the course of the disease. This makes it challenging to dissect whether such changes in the microbiome are initiating or driving factors in autoimmune liver diseases, secondary consequences of disease and/or pharmacological intervention, or alterations that modify the clinical course that patients experience. Potential mechanisms include the presence of pathobionts, disease-modifying microbial metabolites, and more nonspecific reduced gut barrier function, and it is highly likely that the effect of these change during the progression of the disease. Recurrent disease after liver transplantation is a major clinical challenge and a common denominator in these conditions, which could also represent a window to disease mechanisms of the gut-liver axis. Herein, we propose future research priorities, which should involve clinical trials, extensive molecular phenotyping at high resolution, and experimental studies in model systems. Overall, autoimmune liver diseases are characterized by an altered microbiome, and interventions targeting these changes hold promise for improving clinical care based on the emerging field of microbiota medicine.

show abstract

National incidence of autoimmune liver diseases and its relationship with the human development index

Cited by 10 publications

References 46 publications

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Recent advances in the diagnosis and treatment of primary biliary cholangitis

Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts

Role of microbiome in autoimmune liver diseases

Contact Info

Product

Resources

About